Equities research analysts forecast that CareDx, Inc. (NASDAQ:CDNA) will report sales of $12.01 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for CareDx’s earnings, with the lowest sales estimate coming in at $11.69 million and the highest estimate coming in at $12.33 million. CareDx posted sales of $12.48 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 3.8%. The business is expected to report its next earnings report on Wednesday, November 8th.

On average, analysts expect that CareDx will report full year sales of $12.01 million for the current year, with estimates ranging from $46.65 million to $46.70 million. For the next financial year, analysts expect that the company will report sales of $55.20 million per share. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow CareDx.

CareDx (NASDAQ:CDNA) last announced its earnings results on Thursday, August 10th. The company reported ($0.19) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.19). The company had revenue of $12.05 million during the quarter, compared to analyst estimates of $11.87 million. CareDx had a negative return on equity of 69.67% and a negative net margin of 77.02%.

Several research firms have commented on CDNA. Zacks Investment Research downgraded CareDx from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. ValuEngine cut CareDx from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.

Shares of CareDx (CDNA) traded up 14.9776% during mid-day trading on Friday, reaching $1.5407. The company had a trading volume of 204,666 shares. The firm’s 50-day moving average price is $1.26 and its 200 day moving average price is $1.48. The company’s market cap is $33.00 million. CareDx has a 52-week low of $0.76 and a 52-week high of $5.00.

In related news, major shareholder Neil Gagnon bought 63,120 shares of the company’s stock in a transaction dated Friday, June 23rd. The shares were bought at an average price of $1.10 per share, for a total transaction of $69,432.00. Following the completion of the acquisition, the insider now directly owns 886,216 shares of the company’s stock, valued at $974,837.60. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders bought 80,689 shares of company stock worth $87,815 in the last 90 days. Corporate insiders own 5.40% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. Royce & Associates LP boosted its position in shares of CareDx by 23.5% in the first quarter. Royce & Associates LP now owns 526,472 shares of the company’s stock valued at $737,000 after buying an additional 100,111 shares during the period. Gagnon Securities LLC boosted its position in CareDx by 2.9% in the second quarter. Gagnon Securities LLC now owns 2,084,292 shares of the company’s stock valued at $2,314,000 after buying an additional 57,954 shares during the last quarter. Finally, Armstrong Henry H Associates Inc. acquired a new position in CareDx during the first quarter valued at approximately $22,450,000. Institutional investors own 34.89% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was first reported by Daily Political and is owned by of Daily Political. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/08/11/caredx-inc-nasdaqcdna-expected-to-post-quarterly-sales-of-12-01-million.html.

CareDx Company Profile

CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.

Get a free copy of the Zacks research report on CareDx (CDNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.